Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
谷氨酰胺酶抑制剂药物的发现和基于纳米颗粒的胰腺癌治疗递送
基本信息
- 批准号:9028315
- 负责人:
- 金额:$ 42.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2020-11-30
- 项目状态:已结题
- 来源:
- 关键词:AbraxaneAdjuvant ChemotherapyAlbuminsAmino AcidsAmmoniaAttenuatedBindingBiological AssayBlood CirculationCancer EtiologyCancer ModelCancer PatientCellsCessation of lifeCharacteristicsClinicClinicalCollaborationsCytidine DeaminaseDetectionDiseaseDoseDoxorubicin Hydrochloride LiposomeDrug Delivery SystemsDrug ExposureDrug KineticsEffectivenessEnergy-Generating ResourcesEnzymesFormulationGenesGlutamatesGlutaminaseGlutamineGlycolatesGoalsGrowthHealthHomologous GeneHumanImmune systemIn VitroKRAS2 geneKnowledgeLaboratoriesLegal patentMalignant NeoplasmsMalignant neoplasm of pancreasMetabolismMethodsModelingMolecularMusMutateMutationOncogenicOperative Surgical ProceduresPaclitaxelPancreasPancreatic Ductal AdenocarcinomaPathologyPatientsPenetrationPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPre-Clinical ModelProductionPropertyRattusReactive Oxygen SpeciesReportingStructureStructure-Activity RelationshipSulfidesSurfaceTestingTherapeutic IndexTimeTissuesToxic effectTranslatingTumor TissueViral OncogeneXenograft procedureanalogbasecancer cellcancer therapyclinically relevantdensitydeprivationdesigndrug discoverydrug efficacyethylene glycolgemcitabineimprovedimproved outcomein vivoinhibitor/antagonistintravenous injectionmeetingsmouse modelnanomedicinenanoparticlenanosizednovelnovel strategiesoncologyoutcome forecastpancreatic cancer cellspancreatic neoplasmprototypesarcomasmall moleculesuccesstumortumor metabolism
项目摘要
DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal diseases despite continual improvements in therapy. Thus new approaches are sorely needed. Mutations in the oncogenic KRAS gene occur in over 90% of PDACs. KRAS is a known regulator of glutamine metabolism that renders cancer cells dependent on glutamine. Therefore, targeting glutamine metabolism may be particularly effective in treating a large portion of patients with pancreatic cancer. The first step of glutamie metabolism is the conversion of glutamine to glutamate via glutaminase. We have demonstrated that small molecule glutaminase inhibitors, such as BPTES (bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide), block the production of glutamine in pancreatic cancer cells and attenuate growth rates in both in vitro and in vivo preclinical models. However, BPTES and other available glutaminase inhibitors are generally poorly soluble, metabolically unstable, nonselective, and/or require high doses, which reduce their efficacy and therapeutic index. Recently, nano-sized vehicles to enhance drug delivery in cancer have been approved (e.g. Doxil(r), Abraxane(r)) and have been rationalized as an approach to circumvent the stromal barrier which is a clinical challenge to drug delivery in pancreatic cancer. We recently demonstrated that nanoparticle delivery of BPTES can be safely administered and relative to free BPTES, provides dramatic improvement in tumor drug exposure and retention, resulting in greater efficacy. We have now identified several proprietary BPTES derivatives that are 10- to 100-fold more potent than BPTES and, at the same time, retain the key physicochemical properties (cLogP, PSA) required for nanoparticle encapsulation and delivery. We plan to further optimize the potency of the glutaminase inhibitors (Aim 1) and their compatibility to encapsulation (Aim 2) and evaluate their effectiveness in orthotopic xenografts from KRAS mutated patient-derived pancreatic tumors as well as KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ (or KPC) mice that develop natural pancreatic tumors with characteristic stroma (Aim 3). Ultimately, we seek to translate these findings into the clinic and improve outcomes for pancreatic cancer patients. The proposal builds on the complementary strengths of the three collaborating laboratories - Slusher (small molecule drug discovery), Hanes (nanoparticle design), and Le (cancer metabolism).
描述(由申请人提供):尽管治疗方法不断改进,但胰腺导管腺癌(PDAC)仍然是最致命的疾病之一。因此,迫切需要新的方法。致癌KRAS基因突变发生在超过90%的PDAC中。KRAS是一种已知的谷氨酰胺代谢调节剂,使癌细胞依赖于谷氨酰胺。因此,靶向谷氨酰胺代谢可能对治疗大部分胰腺癌患者特别有效。谷氨酰胺代谢的第一步是通过谷氨酰胺酶将谷氨酰胺转化为谷氨酸。我们已经证明,小分子谷氨酰胺酶抑制剂,如BPTES(双-2-[5-(苯乙酰氨基)-1,3,4-噻二唑-2-基]乙基硫醚),阻断胰腺癌细胞中谷氨酰胺的产生,并在体外和体内临床前模型中减弱生长速率。然而,BPTES和其他可用的转氨酶抑制剂通常溶解性差、代谢不稳定、非选择性和/或需要高剂量,这降低了它们的功效和治疗指数。最近,用于增强癌症中药物递送的纳米尺寸的载体已经被批准(例如Doxil(r)、Abraxane(r)),并且已经被合理化为绕过间质屏障的方法,所述间质屏障是胰腺癌中药物递送的临床挑战。我们最近证明,BPTES的纳米颗粒递送可以安全地施用,并且相对于游离BPTES,提供了肿瘤药物暴露和保留的显著改善,从而产生更大的功效。我们现在已经确定了几种专有的BPTES衍生物,其效力是BPTES的10至100倍,同时保留了纳米颗粒包封和递送所需的关键理化性质(cLogP,PSA)。我们计划进一步优化转氨酶抑制剂的效力(目标1)及其与包封的相容性(目标2),并评估其在来自KRAS突变的患者来源的胰腺肿瘤以及发展具有特征性基质的天然胰腺肿瘤的KrasLSL.G12D/+; p53 R172 H/+; Pdxlag/+(或KPC)小鼠的原位异种移植物中的有效性(目标3)。最终,我们寻求将这些发现转化为临床,并改善胰腺癌患者的预后。该提案建立在三个合作实验室的互补优势之上- Slusher(小分子药物发现),Hanes(纳米颗粒设计)和Le(癌症代谢)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin S. Hanes其他文献
Justin S. Hanes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Justin S. Hanes', 18)}}的其他基金
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas
聚焦超声预处理增强纳米颗粒在浸润性神经胶质瘤中的渗透
- 批准号:
10375573 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas
聚焦超声预处理增强纳米颗粒在浸润性神经胶质瘤中的渗透
- 批准号:
10210648 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas
聚焦超声预处理增强纳米颗粒在浸润性神经胶质瘤中的渗透
- 批准号:
10541232 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
脑部穿透性 DNA 纳米颗粒靶向递送至脑肿瘤
- 批准号:
9083426 - 财政年份:2016
- 资助金额:
$ 42.56万 - 项目类别:
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
脑部穿透性 DNA 纳米颗粒靶向递送至脑肿瘤
- 批准号:
9260870 - 财政年份:2016
- 资助金额:
$ 42.56万 - 项目类别:
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
脑部穿透性 DNA 纳米颗粒靶向递送至脑肿瘤
- 批准号:
9891031 - 财政年份:2016
- 资助金额:
$ 42.56万 - 项目类别:
Biodegradable Mucus Penetrating DNA Nanoparticle for Gene Therapy of CF
用于 CF 基因治疗的可生物降解粘液穿透 DNA 纳米颗粒
- 批准号:
8863900 - 财政年份:2015
- 资助金额:
$ 42.56万 - 项目类别:
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD
粘液微观结构和渗透压:COPD 中 CB 的生物标志物
- 批准号:
8852864 - 财政年份:2015
- 资助金额:
$ 42.56万 - 项目类别:
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
谷氨酰胺酶抑制剂药物的发现和基于纳米颗粒的胰腺癌治疗递送
- 批准号:
9188044 - 财政年份:2015
- 资助金额:
$ 42.56万 - 项目类别:
Biodegradable Mucus Penetrating DNA Nanoparticle for Gene Therapy of CF
用于 CF 基因治疗的可生物降解粘液穿透 DNA 纳米颗粒
- 批准号:
9229059 - 财政年份:2015
- 资助金额:
$ 42.56万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 42.56万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 42.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 42.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 42.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 42.56万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 42.56万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 42.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)